# A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

> **NCT06025110** · PHASE2 · TERMINATED · sponsor: **ITB-Med LLC** · enrollment: 9 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **BIOLOGICAL:** TCD601
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06025110
- **Lead sponsor:** ITB-Med LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-23
- **Primary completion:** 2025-07-24
- **Final completion:** 2025-07-24
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** The study has been early terminated due to business reasons. This decision is not related to any safety, efficacy, or regulatory concerns.
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06025110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06025110, "A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT06025110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*